TY - JOUR PY - 2015 DA - 2015// TI - 2015 Alzheimer’s disease facts and figures JO - Alzheimers Dement VL - 11 UR - https://doi.org/10.1016/j.jalz.2015.02.003 DO - 10.1016/j.jalz.2015.02.003 ID - ref1 ER - TY - STD TI - Alzheimer's Association. 2016 Alzheimer’s disease facts and figures. Alzheimer Dement. 2016;12(4):459–509. ID - ref2 ER - TY - JOUR AU - Mar, J. AU - Soto-Gordoa, M. AU - Arrospide, A. AU - Moreno-Izco, F. AU - Martinez-Lage, P. PY - 2015 DA - 2015// TI - Fitting the epidemiology and neuropathology of the early stages of Alzheimer’s disease to prevent dementia JO - Alzheimers Res Ther VL - 7 UR - https://doi.org/10.1186/s13195-014-0079-9 DO - 10.1186/s13195-014-0079-9 ID - Mar2015 ER - TY - JOUR AU - Brookmeyer, R. AU - Johnson, E. AU - Ziegler-Graham, K. AU - Arrighi, H. M. PY - 2007 DA - 2007// TI - Forecasting the global burden of Alzheimer’s disease JO - Alzheimers Dement VL - 3 UR - https://doi.org/10.1016/j.jalz.2007.04.381 DO - 10.1016/j.jalz.2007.04.381 ID - Brookmeyer2007 ER - TY - JOUR PY - 2017 DA - 2017// TI - 2017 Alzheimer’s disease facts and figures JO - Alzheimers Dement VL - 13 UR - https://doi.org/10.1016/j.jalz.2017.02.001 DO - 10.1016/j.jalz.2017.02.001 ID - ref5 ER - TY - JOUR AU - Hurd, M. D. AU - Martorell, P. AU - Langa, K. M. PY - 2013 DA - 2013// TI - Monetary costs of dementia in the United States JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMc1305541 DO - 10.1056/NEJMc1305541 ID - Hurd2013 ER - TY - JOUR AU - Cummings, J. L. AU - Morstorf, T. AU - Zhong, K. PY - 2014 DA - 2014// TI - Alzheimer’s disease drug-development pipeline: few candidates, frequent failures JO - Alzheimers Res Ther VL - 6 UR - https://doi.org/10.1186/alzrt269 DO - 10.1186/alzrt269 ID - Cummings2014 ER - TY - JOUR AU - Cummings, J. AU - Lee, G. AU - Mortsdorf, T. AU - Ritter, A. AU - Zhong, K. PY - 2017 DA - 2017// TI - Alzheimer’s disease drug development pipeline: 2017 JO - Alzheimers Dement VL - 3 ID - Cummings2017 ER - TY - JOUR AU - Cummings, J. AU - Lee, G. AU - Ritter, A. AU - Zhong, K. PY - 2018 DA - 2018// TI - Alzheimer’s disease drug development pipeline: 2018 JO - Alzheimers Dement VL - 4 ID - Cummings2018 ER - TY - JOUR AU - Moser, J. AU - Verdin, P. PY - 2018 DA - 2018// TI - Trial watch: burgeoning oncology pipeline raises questions about sustainability JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2018.165 DO - 10.1038/nrd.2018.165 ID - Moser2018 ER - TY - JOUR AU - Hampel, H. AU - O’Bryant, S. E. AU - Castrillo, J. I. AU - Ritchie, C. AU - Rojkova, K. AU - Broich, K. PY - 2016 DA - 2016// TI - Precision medicine - the golden gate for detection, treatment and prevention of Alzheimer’s disease JO - J Prev Alzheimers Dis. VL - 3 ID - Hampel2016 ER - TY - JOUR AU - Hampel, H. AU - O’Bryant, S. E. AU - Durrleman, S. AU - Younesi, E. AU - Rojkova, K. AU - Escott-Price, V. PY - 2017 DA - 2017// TI - A precision medicine initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling JO - Climacteric. VL - 20 UR - https://doi.org/10.1080/13697137.2017.1287866 DO - 10.1080/13697137.2017.1287866 ID - Hampel2017 ER - TY - JOUR AU - Peng, X. AU - Xing, P. AU - Li, X. AU - Qian, Y. AU - Song, F. AU - Bai, Z. PY - 2016 DA - 2016// TI - Towards personalized intervention for Alzheimer’s disease JO - Genomics Proteomics Bioinformatics VL - 14 UR - https://doi.org/10.1016/j.gpb.2016.01.006 DO - 10.1016/j.gpb.2016.01.006 ID - Peng2016 ER - TY - JOUR AU - Plenge, R. M. PY - 2016 DA - 2016// TI - Disciplined approach to drug discovery and early development JO - Sci Transl Med VL - 8 UR - https://doi.org/10.1126/scitranslmed.aaf2608 DO - 10.1126/scitranslmed.aaf2608 ID - Plenge2016 ER - TY - JOUR AU - Morgan, P. AU - Brown, D. G. AU - Lennard, S. AU - Anderton, M. J. AU - Barrett, J. C. AU - Eriksson, U. PY - 2018 DA - 2018// TI - Impact of a five-dimensional framework on R&D productivity at AstraZeneca JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2017.244 DO - 10.1038/nrd.2017.244 ID - Morgan2018 ER - TY - JOUR AU - Golde, T. E. AU - DeKosky, S. T. AU - Galasko, D. PY - 2018 DA - 2018// TI - Alzheimer’s disease: the right drug, the right time JO - Science VL - 362 UR - https://doi.org/10.1126/science.aau0437 DO - 10.1126/science.aau0437 ID - Golde2018 ER - TY - JOUR AU - Morgan, P. AU - Graaf, P. H. AU - Arrowsmith, J. AU - Feltner, D. E. AU - Drummond, K. S. AU - Wegner, C. D. PY - 2012 DA - 2012// TI - Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival JO - Drug Discov Today VL - 17 UR - https://doi.org/10.1016/j.drudis.2011.12.020 DO - 10.1016/j.drudis.2011.12.020 ID - Morgan2012 ER - TY - JOUR AU - Milligan, P. A. AU - Brown, M. J. AU - Marchant, B. AU - Martin, S. W. AU - Graaf, P. H. AU - Benson, N. PY - 2013 DA - 2013// TI - Model-based drug development: a rational approach to efficiently accelerate drug development JO - Clin Pharmacol Ther VL - 93 UR - https://doi.org/10.1038/clpt.2013.54 DO - 10.1038/clpt.2013.54 ID - Milligan2013 ER - TY - JOUR AU - Visser, S. A. AU - Aurell, M. AU - Jones, R. D. AU - Schuck, V. J. AU - Egnell, A. C. AU - Peters, S. A. PY - 2013 DA - 2013// TI - Model-based drug discovery: implementation and impact JO - Drug Discov Today VL - 18 UR - https://doi.org/10.1016/j.drudis.2013.05.012 DO - 10.1016/j.drudis.2013.05.012 ID - Visser2013 ER - TY - JOUR AU - Dolgos, H. AU - Trusheim, M. AU - Gross, D. AU - Halle, J. P. AU - Ogden, J. AU - Osterwalder, B. PY - 2016 DA - 2016// TI - Translational medicine guide transforms drug development processes: the recent Merck experience JO - Drug Discov Today VL - 21 UR - https://doi.org/10.1016/j.drudis.2016.01.003 DO - 10.1016/j.drudis.2016.01.003 ID - Dolgos2016 ER - TY - JOUR AU - Cook, D. AU - Brown, D. AU - Alexander, R. AU - March, R. AU - Morgan, P. AU - Satterthwaite, G. PY - 2014 DA - 2014// TI - Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4309 DO - 10.1038/nrd4309 ID - Cook2014 ER - TY - JOUR AU - Cummings, J. PY - 2017 DA - 2017// TI - Lessons learned from Alzheimer disease: clinical trials with negative outcomes JO - Clin Transl Sci VL - 11 UR - https://doi.org/10.1111/cts.12491 DO - 10.1111/cts.12491 ID - Cummings2017 ER - TY - JOUR AU - Becker, R. E. AU - Greig, N. H. PY - 2012 DA - 2012// TI - Increasing the success rate for Alzheimer’s disease drug discovery and development JO - Expert Opin Drug Discov VL - 7 UR - https://doi.org/10.1517/17460441.2012.672409 DO - 10.1517/17460441.2012.672409 ID - Becker2012 ER - TY - JOUR AU - Karran, E. AU - Hardy, J. PY - 2014 DA - 2014// TI - A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease JO - Ann Neurol VL - 76 UR - https://doi.org/10.1002/ana.24188 DO - 10.1002/ana.24188 ID - Karran2014 ER - TY - JOUR AU - Kobayashi, H. AU - Ohnishi, T. AU - Nakagawa, R. AU - Yoshizawa, K. PY - 2016 DA - 2016// TI - The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: a Bayesian network meta-analysis JO - Int J Geriatr Psychiatry VL - 31 UR - https://doi.org/10.1002/gps.4405 DO - 10.1002/gps.4405 ID - Kobayashi2016 ER - TY - JOUR AU - Tan, C. C. AU - Yu, J. T. AU - Wang, H. F. AU - Tan, M. S. AU - Meng, X. F. AU - Wang, C. PY - 2014 DA - 2014// TI - Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis JO - J Alzheimers Dis VL - 41 UR - https://doi.org/10.3233/JAD-132690 DO - 10.3233/JAD-132690 ID - Tan2014 ER - TY - JOUR AU - Tariot, P. N. AU - Farlow, M. R. AU - Grossberg, G. T. AU - Graham, S. M. AU - McDonald, S. AU - Gergel, I. PY - 2004 DA - 2004// TI - Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial JO - JAMA. VL - 291 UR - https://doi.org/10.1001/jama.291.3.317 DO - 10.1001/jama.291.3.317 ID - Tariot2004 ER - TY - JOUR AU - Doody, R. S. AU - Tariot, P. N. AU - Pfeiffer, E. AU - Olin, J. T. AU - Graham, S. M. PY - 2007 DA - 2007// TI - Meta-analysis of six-month memantine trials in Alzheimer’s disease JO - Alzheimers Dement VL - 3 UR - https://doi.org/10.1016/j.jalz.2006.10.004 DO - 10.1016/j.jalz.2006.10.004 ID - Doody2007 ER - TY - JOUR AU - Greig, S. L. PY - 2015 DA - 2015// TI - Memantine ER/donepezil: a review in Alzheimer’s disease JO - CNS Drugs VL - 29 UR - https://doi.org/10.1007/s40263-015-0287-2 DO - 10.1007/s40263-015-0287-2 ID - Greig2015 ER - TY - JOUR AU - Reisberg, B. AU - Doody, R. AU - Stoffler, A. AU - Schmitt, F. AU - Ferris, S. AU - Mobius, H. J. PY - 2003 DA - 2003// TI - Memantine in moderate-to-severe Alzheimer’s disease JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa013128 DO - 10.1056/NEJMoa013128 ID - Reisberg2003 ER - TY - JOUR AU - Strohle, A. AU - Schmidt, D. K. AU - Schultz, F. AU - Fricke, N. AU - Staden, T. AU - Hellweg, R. PY - 2015 DA - 2015// TI - Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials JO - Am J Geriatr Psychiatry VL - 23 UR - https://doi.org/10.1016/j.jagp.2015.07.007 DO - 10.1016/j.jagp.2015.07.007 ID - Strohle2015 ER - TY - JOUR AU - Sevigny, J. AU - Chiao, P. AU - Bussiere, T. AU - Weinreb, P. H. AU - Williams, L. AU - Maier, M. PY - 2016 DA - 2016// TI - The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease JO - Nature. VL - 537 UR - https://doi.org/10.1038/nature19323 DO - 10.1038/nature19323 ID - Sevigny2016 ER - TY - JOUR AU - Cummings, J. L. AU - Fox, N. PY - 2017 DA - 2017// TI - Defining disease modification for Alzheimer’s disease clinical trials JO - J Prev Alz Dis VL - 4 ID - Cummings2017 ER - TY - JOUR AU - Fauman, E. B. AU - Rai, B. K. AU - Huang, E. S. PY - 2011 DA - 2011// TI - Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics JO - Curr Opin Chem Biol VL - 15 UR - https://doi.org/10.1016/j.cbpa.2011.05.020 DO - 10.1016/j.cbpa.2011.05.020 ID - Fauman2011 ER - TY - JOUR AU - Gashaw, I. AU - Ellinghaus, P. AU - Sommer, A. AU - Asadullah, K. PY - 2011 DA - 2011// TI - What makes a good drug target? JO - Drug Discov Today VL - 16 UR - https://doi.org/10.1016/j.drudis.2011.09.007 DO - 10.1016/j.drudis.2011.09.007 ID - Gashaw2011 ER - TY - JOUR AU - Gashaw, I. AU - Ellinghaus, P. AU - Sommer, A. AU - Asadullah, K. PY - 2012 DA - 2012// TI - What makes a good drug target? JO - Drug Discov Today VL - 17 UR - https://doi.org/10.1016/j.drudis.2011.12.008 DO - 10.1016/j.drudis.2011.12.008 ID - Gashaw2012 ER - TY - JOUR AU - Lo, A. W. AU - Ho, C. AU - Cummings, J. AU - Kosik, K. S. PY - 2014 DA - 2014// TI - Parallel discovery of Alzheimer’s therapeutics JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008228 DO - 10.1126/scitranslmed.3008228 ID - Lo2014 ER - TY - JOUR AU - Refolo, L. M. AU - Snyder, H. AU - Liggins, C. AU - Ryan, L. AU - Silverberg, N. AU - Petanceska, S. PY - 2012 DA - 2012// TI - Common Alzheimer’s disease research ontology: National Institute on Aging and Alzheimer’s Association collaborative project JO - Alzheimers Dement VL - 8 UR - https://doi.org/10.1016/j.jalz.2012.05.2115 DO - 10.1016/j.jalz.2012.05.2115 ID - Refolo2012 ER - TY - JOUR AU - Tabrizi, S. J. AU - Leavitt, B. R. AU - Landwehrmeyer, G. B. AU - Wild, E. J. AU - Saft, C. AU - Barker, R. A. PY - 2019 DA - 2019// TI - Targeting huntingtin expression in patients with Huntington’s disease JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1900907 DO - 10.1056/NEJMoa1900907 ID - Tabrizi2019 ER - TY - JOUR AU - Schneider, L. S. AU - Raman, R. AU - Schmitt, F. A. AU - Doody, R. S. AU - Insel, P. AU - Clark, C. M. PY - 2009 DA - 2009// TI - Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials JO - Alzheimer Dis Assoc Disord VL - 23 UR - https://doi.org/10.1097/WAD.0b013e31819cb760 DO - 10.1097/WAD.0b013e31819cb760 ID - Schneider2009 ER - TY - JOUR AU - Schneider, J. A. AU - Arvanitakis, Z. AU - Leurgans, S. E. AU - Bennett, D. A. PY - 2009 DA - 2009// TI - The neuropathology of probable Alzheimer disease and mild cognitive impairment JO - Ann Neurol VL - 66 UR - https://doi.org/10.1002/ana.21706 DO - 10.1002/ana.21706 ID - Schneider2009 ER - TY - JOUR AU - Woodward, M. AU - Mackenzie, I. R. A. AU - Hsiung, G. Y. AU - Jacova, C. AU - Feldman, H. PY - 2010 DA - 2010// TI - Multiple brain pathologies in dementia are common JO - Eur Ger Med VL - 1 UR - https://doi.org/10.1016/j.eurger.2010.07.012 DO - 10.1016/j.eurger.2010.07.012 ID - Woodward2010 ER - TY - JOUR AU - Devi, G. AU - Scheltens, P. PY - 2018 DA - 2018// TI - Heterogeneity of Alzheimer’s disease: consequence for drug trials? JO - Alzheimers Res Ther VL - 10 UR - https://doi.org/10.1186/s13195-018-0455-y DO - 10.1186/s13195-018-0455-y ID - Devi2018 ER - TY - JOUR AU - Plenge, R. M. AU - Scolnick, E. M. AU - Altshuler, D. PY - 2013 DA - 2013// TI - Validating therapeutic targets through human genetics JO - Nat Rev Drug Discov VL - 12 UR - https://doi.org/10.1038/nrd4051 DO - 10.1038/nrd4051 ID - Plenge2013 ER - TY - JOUR AU - Li, P. AU - Nie, Y. AU - Yu, J. PY - 2015 DA - 2015// TI - An effective method to identify shared pathways and common factors among neurodegenerative diseases JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0143045 DO - 10.1371/journal.pone.0143045 ID - Li2015 ER - TY - JOUR PY - 2015 DA - 2015// TI - Convergent genetic and expression data implicate immunity in Alzheimer’s disease JO - Alzheimer Dement VL - 11 UR - https://doi.org/10.1016/j.jalz.2014.05.1757 DO - 10.1016/j.jalz.2014.05.1757 ID - ref46 ER - TY - JOUR AU - Guerreiro, R. AU - Hardy, J. PY - 2014 DA - 2014// TI - Genetics of Alzheimer’s disease JO - Neurotherapeutics. VL - 11 UR - https://doi.org/10.1007/s13311-014-0295-9 DO - 10.1007/s13311-014-0295-9 ID - Guerreiro2014 ER - TY - JOUR AU - Townsend, M. J. AU - Arron, J. R. PY - 2016 DA - 2016// TI - Reducing the risk of failure: biomarker-guided trial design JO - Nat Rev Drug Discov VL - 15 UR - https://doi.org/10.1038/nrd.2016.124 DO - 10.1038/nrd.2016.124 ID - Townsend2016 ER - TY - JOUR AU - Kosik, K. S. AU - Sejnowski, T. J. AU - Raichle, M. E. AU - Ciechanover, A. AU - Baltimore, D. PY - 2016 DA - 2016// TI - A path toward understanding neurodegeneration JO - Science. VL - 353 UR - https://doi.org/10.1126/science.aai7622 DO - 10.1126/science.aai7622 ID - Kosik2016 ER - TY - JOUR AU - Breder, C. D. AU - Du, W. AU - Tyndall, A. PY - 2017 DA - 2017// TI - What’s the regulatory value of a target product profile? JO - Trends Biotechnol VL - 35 UR - https://doi.org/10.1016/j.tibtech.2017.02.011 DO - 10.1016/j.tibtech.2017.02.011 ID - Breder2017 ER - TY - JOUR AU - Wyatt, P. G. AU - Gilbert, I. H. AU - Read, K. D. AU - Fairlamb, A. H. PY - 2011 DA - 2011// TI - Target validation: linking target and chemical properties to desired product profile JO - Curr Top Med Chem VL - 11 UR - https://doi.org/10.2174/156802611795429185 DO - 10.2174/156802611795429185 ID - Wyatt2011 ER - TY - STD TI - Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis. 2017; In press. ID - ref52 ER - TY - JOUR AU - Banks, W. A. PY - 2008 DA - 2008// TI - Developing drugs that can cross the blood-brain barrier: applications to Alzheimer’s disease JO - BMC Neurosci VL - 9 UR - https://doi.org/10.1186/1471-2202-9-S3-S2 DO - 10.1186/1471-2202-9-S3-S2 ID - Banks2008 ER - TY - JOUR AU - Walters, W. P. PY - 2012 DA - 2012// TI - Going further than Lipinski’s rule in drug design JO - Expert Opin Drug Discov. VL - 7 UR - https://doi.org/10.1517/17460441.2012.648612 DO - 10.1517/17460441.2012.648612 ID - Walters2012 ER - TY - JOUR AU - Ticehurst, M. D. AU - Marziano, I. PY - 2015 DA - 2015// TI - Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design JO - J Pharm Pharmacol VL - 67 UR - https://doi.org/10.1111/jphp.12375 DO - 10.1111/jphp.12375 ID - Ticehurst2015 ER - TY - JOUR AU - Mignani, S. AU - Huber, S. AU - Tomas, H. AU - Rodrigues, J. AU - Majoral, J. P. PY - 2016 DA - 2016// TI - Compound high-quality criteria: a new vision to guide the development of drugs, current situation JO - Drug Discov Today VL - 21 UR - https://doi.org/10.1016/j.drudis.2016.01.005 DO - 10.1016/j.drudis.2016.01.005 ID - Mignani2016 ER - TY - JOUR AU - Steinmetz, K. L. AU - Spack, E. G. PY - 2009 DA - 2009// TI - The basics of preclinical drug development for neurodegenerative disease indications JO - BMC Neurol VL - 9 UR - https://doi.org/10.1186/1471-2377-9-S1-S2 DO - 10.1186/1471-2377-9-S1-S2 ID - Steinmetz2009 ER - TY - JOUR AU - Lacombe, O. AU - Videau, O. AU - Chevillon, D. AU - Guyot, A. C. AU - Contreras, C. AU - Blondel, S. PY - 2011 DA - 2011// TI - In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery JO - Mol Pharm VL - 8 UR - https://doi.org/10.1021/mp1004614 DO - 10.1021/mp1004614 ID - Lacombe2011 ER - TY - JOUR AU - Lin, J. H. PY - 2008 DA - 2008// TI - CSF as a surrogate for assessing CNS exposure: an industrial perspective JO - Curr Drug Metab VL - 9 UR - https://doi.org/10.2174/138920008783331077 DO - 10.2174/138920008783331077 ID - Lin2008 ER - TY - JOUR AU - Shen, D. D. AU - Artru, A. A. AU - Adkison, K. K. PY - 2004 DA - 2004// TI - Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics JO - Adv Drug Deliv Rev VL - 56 UR - https://doi.org/10.1016/j.addr.2004.07.011 DO - 10.1016/j.addr.2004.07.011 ID - Shen2004 ER - TY - JOUR AU - Rizk, M. L. AU - Zou, L. AU - Savic, R. M. AU - Dooley, K. E. PY - 2017 DA - 2017// TI - Importance of drug pharmacokinetics at the site of action JO - Clin Transl Sci. VL - 10 UR - https://doi.org/10.1111/cts.12448 DO - 10.1111/cts.12448 ID - Rizk2017 ER - TY - JOUR AU - Wan, H. I. AU - Jacobsen, J. S. AU - Rutkowski, J. L. AU - Feuerstein, G. Z. PY - 2009 DA - 2009// TI - Translational medicine lessons from flurizan’s failure in Alzheimer’s disease (AD) trial: implication for future drug discovery and development for AD JO - Clin Transl Sci. VL - 2 UR - https://doi.org/10.1111/j.1752-8062.2009.00121.x DO - 10.1111/j.1752-8062.2009.00121.x ID - Wan2009 ER - TY - JOUR AU - Ameen-Ali, K. E. AU - Wharton, S. B. AU - Simpson, J. E. AU - Heath, P. R. AU - Sharp, P. AU - Berwick, J. PY - 2017 DA - 2017// TI - Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease JO - Neuropathology and Applied Neurobiology VL - 43 UR - https://doi.org/10.1111/nan.12440 DO - 10.1111/nan.12440 ID - Ameen-Ali2017 ER - TY - JOUR AU - Sabbagh, J. J. AU - Kinney, J. W. AU - Cummings, J. L. PY - 2013 DA - 2013// TI - Animal systems in the development of treatments for Alzheimer’s disease: challenges, methods, and implications JO - Neurobiol Aging VL - 34 UR - https://doi.org/10.1016/j.neurobiolaging.2012.02.027 DO - 10.1016/j.neurobiolaging.2012.02.027 ID - Sabbagh2013 ER - TY - JOUR AU - Laurijssens, B. AU - Aujard, F. AU - Rahman, A. PY - 2013 DA - 2013// TI - Animal models of Alzheimer’s disease and drug development JO - Drug Discov Today Technol VL - 10 UR - https://doi.org/10.1016/j.ddtec.2012.04.001 DO - 10.1016/j.ddtec.2012.04.001 ID - Laurijssens2013 ER - TY - JOUR AU - Potter, R. AU - Patterson, B. W. AU - Elbert, D. L. AU - Ovod, V. AU - Kasten, T. AU - Sigurdson, W. PY - 2013 DA - 2013// TI - Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3005615 DO - 10.1126/scitranslmed.3005615 ID - Potter2013 ER - TY - JOUR AU - Xu, G. AU - Ran, Y. AU - Fromholt, S. E. AU - Fu, C. AU - Yachnis, A. T. AU - Golde, T. E. PY - 2015 DA - 2015// TI - Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits JO - Acta Neuropathol Commun VL - 3 UR - https://doi.org/10.1186/s40478-015-0252-9 DO - 10.1186/s40478-015-0252-9 ID - Xu2015 ER - TY - JOUR AU - Sabbagh, J. J. AU - Kinney, J. W. AU - Cummings, J. L. PY - 2013 DA - 2013// TI - Alzheimer’s disease biomarkers in animal models: closing the translational gap JO - Am J Neurodegener Dis VL - 2 ID - Sabbagh2013 ER - TY - JOUR AU - Yang, J. AU - Li, S. AU - He, X. B. AU - Cheng, C. AU - Le, W. PY - 2016 DA - 2016// TI - Induced pluripotent stem cells in Alzheimer’s disease: applications for disease modeling and cell-replacement therapy JO - Mol Neurodegener VL - 11 UR - https://doi.org/10.1186/s13024-016-0106-3 DO - 10.1186/s13024-016-0106-3 ID - Yang2016 ER - TY - JOUR AU - Liu, Q. AU - Waltz, S. AU - Woodruff, G. AU - Ouyang, J. AU - Israel, M. A. AU - Herrera, C. PY - 2014 DA - 2014// TI - Effect of potent gamma-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers JO - JAMA Neurol. VL - 71 UR - https://doi.org/10.1001/jamaneurol.2014.2482 DO - 10.1001/jamaneurol.2014.2482 ID - Liu2014 ER - TY - JOUR AU - Choi, S. H. AU - Kim, Y. H. AU - Quinti, L. AU - Tanzi, R. E. AU - Kim, D. Y. PY - 2016 DA - 2016// TI - 3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish” JO - Mol Neurodegener VL - 11 UR - https://doi.org/10.1186/s13024-016-0139-7 DO - 10.1186/s13024-016-0139-7 ID - Choi2016 ER - TY - JOUR AU - Pangalos, M. N. AU - Schechter, L. E. AU - Hurko, O. PY - 2007 DA - 2007// TI - Drug development for CNS disorders: strategies for balancing risk and reducing attrition JO - Nat Rev Drug Discov VL - 6 UR - https://doi.org/10.1038/nrd2094 DO - 10.1038/nrd2094 ID - Pangalos2007 ER - TY - JOUR AU - Greenberg, B. D. AU - Carrillo, M. C. AU - Ryan, J. M. AU - Gold, M. AU - Gallagher, K. AU - Grundman, M. PY - 2013 DA - 2013// TI - Improving Alzheimer’s disease phase II clinical trials JO - Alzheimers Dement VL - 9 UR - https://doi.org/10.1016/j.jalz.2012.02.002 DO - 10.1016/j.jalz.2012.02.002 ID - Greenberg2013 ER - TY - JOUR AU - Gray, J. A. AU - Fleet, D. AU - Winblad, B. PY - 2015 DA - 2015// TI - The need for thorough phase II studies in medicines development for Alzheimer’s disease JO - Alzheimers Res Ther VL - 7 UR - https://doi.org/10.1186/s13195-015-0153-y DO - 10.1186/s13195-015-0153-y ID - Gray2015 ER - TY - JOUR AU - Cartwright, M. E. AU - Cohen, S. AU - Fleishaker, J. C. AU - Madani, S. AU - McLeod, J. F. AU - Musser, B. PY - 2010 DA - 2010// TI - Proof of concept: a PhRMA position paper with recommendations for best practice JO - Clin Pharmacol Ther VL - 87 UR - https://doi.org/10.1038/clpt.2009.286 DO - 10.1038/clpt.2009.286 ID - Cartwright2010 ER - TY - JOUR AU - Satlin, A. AU - Wang, J. AU - Logovinsky, V. AU - Berry, S. AU - Swanson, C. AU - Dhadda, S. PY - 2016 DA - 2016// TI - Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease JO - Alzheimers Dement (N Y) VL - 2 ID - Satlin2016 ER - TY - JOUR AU - Dalgaard, L. PY - 2015 DA - 2015// TI - Comparison of minipig, dog, monkey and human drug metabolism and disposition JO - J Pharmacol Toxicol Methods VL - 74 UR - https://doi.org/10.1016/j.vascn.2014.12.005 DO - 10.1016/j.vascn.2014.12.005 ID - Dalgaard2015 ER - TY - JOUR AU - Galijatovic-Idrizbegovic, A. AU - Miller, J. E. AU - Cornell, W. D. AU - Butler, J. A. AU - Wollenberg, G. K. AU - Sistare, F. D. PY - 2016 DA - 2016// TI - Role of chronic toxicology studies in revealing new toxicities JO - Regul Toxicol Pharmacol VL - 82 UR - https://doi.org/10.1016/j.yrtph.2016.10.010 DO - 10.1016/j.yrtph.2016.10.010 ID - Galijatovic-Idrizbegovic2016 ER - TY - JOUR AU - Coric, V. AU - Salloway, S. AU - Dyck, C. H. AU - Dubois, B. AU - Andreasen, N. AU - Brody, M. PY - 2015 DA - 2015// TI - Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial JO - JAMA Neurol. VL - 72 UR - https://doi.org/10.1001/jamaneurol.2015.0607 DO - 10.1001/jamaneurol.2015.0607 ID - Coric2015 ER - TY - JOUR AU - Egan, M. F. AU - Kost, J. AU - Voss, T. AU - Mukai, Y. AU - Aisen, P. S. AU - Cummings, J. L. PY - 2019 DA - 2019// TI - Randomized trial of verubecestat for prodromal Alzheimer’s disease JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMoa1812840 DO - 10.1056/NEJMoa1812840 ID - Egan2019 ER - TY - JOUR AU - Doody, R. S. AU - Raman, R. AU - Sperling, R. A. AU - Seimers, E. AU - Sethuraman, G. AU - Mohs, R. PY - 2015 DA - 2015// TI - Peripheral and central effects of gamma-secretase inhibition by semagacestat in Alzheimer’s disease JO - Alzheimers Res Ther VL - 7 UR - https://doi.org/10.1186/s13195-015-0121-6 DO - 10.1186/s13195-015-0121-6 ID - Doody2015 ER - TY - JOUR AU - Hoffman, K. B. AU - Dimbil, M. AU - Tatonetti, N. P. AU - Kyle, R. F. PY - 2016 DA - 2016// TI - A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports JO - Drug Saf VL - 39 UR - https://doi.org/10.1007/s40264-016-0409-x DO - 10.1007/s40264-016-0409-x ID - Hoffman2016 ER - TY - JOUR AU - Hauber, A. B. AU - Johnson, F. R. AU - Fillit, H. AU - Mohamed, A. F. AU - Leibman, C. AU - Arrighi, H. M. PY - 2009 DA - 2009// TI - Older Americans’ risk-benefit preferences for modifying the course of Alzheimer disease JO - Alzheimer Dis Assoc Disord VL - 23 UR - https://doi.org/10.1097/WAD.0b013e318181e4c7 DO - 10.1097/WAD.0b013e318181e4c7 ID - Hauber2009 ER - TY - JOUR AU - Wehling, M. PY - 2009 DA - 2009// TI - Assessing the translatability of drug projects: what needs to be scored to predict success? JO - Nat Rev Drug Discov VL - 8 UR - https://doi.org/10.1038/nrd2898 DO - 10.1038/nrd2898 ID - Wehling2009 ER - TY - JOUR AU - Wendler, A. AU - Wehling, M. PY - 2017 DA - 2017// TI - Translatability score revisited: differentiation for distinct disease areas JO - J Transl Med VL - 15 UR - https://doi.org/10.1186/s12967-017-1329-y DO - 10.1186/s12967-017-1329-y ID - Wendler2017 ER - TY - JOUR AU - Wendler, A. AU - Wehling, M. PY - 2012 DA - 2012// TI - Translatability scoring in drug development: eight case studies JO - J Transl Med VL - 10 UR - https://doi.org/10.1186/1479-5876-10-39 DO - 10.1186/1479-5876-10-39 ID - Wendler2012 ER - TY - JOUR AU - Figueroa-Magalhaes, M. C. AU - Jelovac, D. AU - Connolly, R. AU - Wolff, A. C. PY - 2014 DA - 2014// TI - Treatment of HER2-positive breast cancer JO - Breast. VL - 23 UR - https://doi.org/10.1016/j.breast.2013.11.011 DO - 10.1016/j.breast.2013.11.011 ID - Figueroa-Magalhaes2014 ER - TY - JOUR AU - Green, D. J. AU - Liu, X. I. AU - Hua, T. AU - Burnham, J. M. AU - Schuck, R. AU - Pacanowski, M. PY - 2018 DA - 2018// TI - Enrichment strategies in pediatric drug development: an analysis of trials submitted to the US Food and Drug Administration JO - Clin Pharmacol Ther VL - 104 UR - https://doi.org/10.1002/cpt.971 DO - 10.1002/cpt.971 ID - Green2018 ER - TY - JOUR AU - Arneric, S. P. AU - Kern, V. D. AU - Stephenson, D. T. PY - 2018 DA - 2018// TI - Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments JO - Biochem Pharmacol VL - 151 UR - https://doi.org/10.1016/j.bcp.2018.01.043 DO - 10.1016/j.bcp.2018.01.043 ID - Arneric2018 ER - TY - JOUR AU - Cummings, J. e. f. f. r. e. y. PY - 2019 DA - 2019// TI - The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials JO - Alzheimer's & Dementia VL - 15 UR - https://doi.org/10.1016/j.jalz.2018.05.006 DO - 10.1016/j.jalz.2018.05.006 ID - Cummings2019 ER - TY - JOUR AU - Jack, C. R. AU - Bennett, D. A. AU - Blennow, K. AU - Carrillo, M. C. AU - Dunn, B. AU - Haeberlein, S. B. PY - 2018 DA - 2018// TI - NIA-AA research framework: toward a biological definition of Alzheimer’s disease JO - Alzheimers Dement VL - 14 UR - https://doi.org/10.1016/j.jalz.2018.02.018 DO - 10.1016/j.jalz.2018.02.018 ID - Jack2018 ER - TY - JOUR AU - Kuhle, J. AU - Disanto, G. AU - Lorscheider, J. AU - Stites, T. AU - Chen, Y. AU - Dahlke, F. PY - 2015 DA - 2015// TI - Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis JO - Neurology. VL - 84 UR - https://doi.org/10.1212/WNL.0000000000001491 DO - 10.1212/WNL.0000000000001491 ID - Kuhle2015 ER - TY - JOUR AU - Molinuevo, J. L. AU - Ayton, S. AU - Batrla, R. AU - Bednar, M. M. AU - Bittner, T. AU - Cummings, J. PY - 2018 DA - 2018// TI - Current state of Alzheimer’s fluid biomarkers JO - Acta Neuropathol VL - 136 UR - https://doi.org/10.1007/s00401-018-1932-x DO - 10.1007/s00401-018-1932-x ID - Molinuevo2018 ER - TY - JOUR AU - Mills, S. M. AU - Mallmann, J. AU - Santacruz, A. M. AU - Fuqua, A. AU - Carril, M. AU - Aisen, P. S. PY - 2013 DA - 2013// TI - Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial JO - Rev Neurol (Paris) VL - 169 UR - https://doi.org/10.1016/j.neurol.2013.07.017 DO - 10.1016/j.neurol.2013.07.017 ID - Mills2013 ER - TY - JOUR AU - Reiman, E. M. AU - Langbaum, J. B. AU - Tariot, P. N. PY - 2010 DA - 2010// TI - Alzheimer’s prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible JO - Biomark Med VL - 4 UR - https://doi.org/10.2217/bmm.09.91 DO - 10.2217/bmm.09.91 ID - Reiman2010 ER - TY - JOUR AU - Qian, J. AU - Wolters, F. J. AU - Beiser, A. AU - Haan, M. AU - Ikram, M. A. AU - Karlawish, J. PY - 2017 DA - 2017// TI - APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts JO - PLoS Med VL - 14 UR - https://doi.org/10.1371/journal.pmed.1002254 DO - 10.1371/journal.pmed.1002254 ID - Qian2017 ER - TY - STD TI - Zeitlow K, Charlambous L, Ng I, Gagrani S, Mihovilovic M, Luo S, et al. The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer’s disease. Biochim Biophys Acta. 2017. ID - ref97 ER - TY - JOUR AU - Boluda, S. AU - Toledo, J. B. AU - Irwin, D. J. AU - Raible, K. M. AU - Byrne, M. D. AU - Lee, E. B. PY - 2014 DA - 2014// TI - A comparison of Abeta amyloid pathology staging systems and correlation with clinical diagnosis JO - Acta Neuropathol VL - 128 UR - https://doi.org/10.1007/s00401-014-1308-9 DO - 10.1007/s00401-014-1308-9 ID - Boluda2014 ER - TY - JOUR AU - Souza, L. C. AU - Sarazin, M. AU - Teixeira-Junior, A. L. AU - Caramelli, P. AU - Santos, A. E. AU - Dubois, B. PY - 2014 DA - 2014// TI - Biological markers of Alzheimer’s disease JO - Arq Neuropsiquiatr VL - 72 UR - https://doi.org/10.1590/0004-282X20130233 DO - 10.1590/0004-282X20130233 ID - Souza2014 ER - TY - JOUR AU - Scholl, M. AU - Lockhart, S. N. AU - Schonhaut, D. R. AU - O’Neil, J. P. AU - Janabi, M. AU - Ossenkoppele, R. PY - 2016 DA - 2016// TI - PET imaging of tau deposition in the aging human brain JO - Neuron. VL - 89 UR - https://doi.org/10.1016/j.neuron.2016.01.028 DO - 10.1016/j.neuron.2016.01.028 ID - Scholl2016 ER - TY - JOUR AU - Sevigny, J. AU - Suhy, J. AU - Chiao, P. AU - Chen, T. AU - Klein, G. AU - Purcell, D. PY - 2016 DA - 2016// TI - Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial JO - Alzheimer Dis Assoc Disord VL - 30 UR - https://doi.org/10.1097/WAD.0000000000000144 DO - 10.1097/WAD.0000000000000144 ID - Sevigny2016 ER - TY - JOUR AU - Jack, C. R. AU - Knopman, D. S. AU - Chetelat, G. AU - Dickson, D. AU - Fagan, A. M. AU - Frisoni, G. B. PY - 2016 DA - 2016// TI - Suspected non-Alzheimer disease pathophysiology--concept and controversy JO - Nat Rev Neurol VL - 12 UR - https://doi.org/10.1038/nrneurol.2015.251 DO - 10.1038/nrneurol.2015.251 ID - Jack2016 ER - TY - JOUR AU - Ballard, C. AU - Atri, A. AU - Boneva, N. AU - Cummings, J. L. AU - Frolich, L. AU - Molinuevo, J. L. PY - 2019 DA - 2019// TI - Enrichment factors for clinical trials in mild-to-moderate Alzheimer’s disease JO - Alzheimers Dement (N Y). VL - 5 ID - Ballard2019 ER - TY - JOUR AU - Soares, H. D. PY - 2010 DA - 2010// TI - The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development JO - Curr Opin Investig Drugs VL - 11 ID - Soares2010 ER - TY - JOUR AU - Wagner, J. A. PY - 2008 DA - 2008// TI - Strategic approach to fit-for-purpose biomarkers in drug development JO - Annu Rev Pharmacol Toxicol VL - 48 UR - https://doi.org/10.1146/annurev.pharmtox.48.113006.094611 DO - 10.1146/annurev.pharmtox.48.113006.094611 ID - Wagner2008 ER - TY - JOUR AU - Bateman, R. J. AU - Munsell, L. Y. AU - Morris, J. C. AU - Swarm, R. AU - Yarasheski, K. E. AU - Holtzman, D. M. PY - 2006 DA - 2006// TI - Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo JO - Nat Med VL - 12 UR - https://doi.org/10.1038/nm1438 DO - 10.1038/nm1438 ID - Bateman2006 ER - TY - JOUR AU - Kennedy, M. E. AU - Stamford, A. W. AU - Chen, X. AU - Cox, K. AU - Cumming, J. N. AU - Dockendorf, M. F. PY - 2016 DA - 2016// TI - The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer’s disease patients JO - Sci Transl Med VL - 8 UR - https://doi.org/10.1126/scitranslmed.aad9704 DO - 10.1126/scitranslmed.aad9704 ID - Kennedy2016 ER - TY - JOUR AU - Scheltens, P. AU - Hallikainen, M. AU - Grimmer, T. AU - Duning, T. AU - Gouw, A. A. AU - Teunissen, C. E. PY - 2018 DA - 2018// TI - Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study JO - Alzheimers Res Ther VL - 10 UR - https://doi.org/10.1186/s13195-018-0431-6 DO - 10.1186/s13195-018-0431-6 ID - Scheltens2018 ER - TY - JOUR AU - Portelius, E. AU - Zetterberg, H. AU - Dean, R. A. AU - Marcil, A. AU - Bourgeois, P. AU - Nutu, M. PY - 2012 DA - 2012// TI - Amyloid-beta (1-15/16) as a marker for gamma-secretase inhibition in Alzheimer’s disease JO - J Alzheimers Dis VL - 31 UR - https://doi.org/10.3233/JAD-2012-120508 DO - 10.3233/JAD-2012-120508 ID - Portelius2012 ER - TY - JOUR AU - Luo, D. AU - Smith, J. A. AU - Meadows, N. A. AU - Schuh, A. AU - Manescu, K. E. AU - Bure, K. PY - 2015 DA - 2015// TI - A quantitative assessment of factors affecting the technological development and adoption of companion diagnostics JO - Front Genet VL - 6 ID - Luo2015 ER - TY - STD TI - Cummings J. The role of biomarkers in Alzheimer’s disease drug development. Adv Exp Med Biol. In Press. ID - ref111 ER - TY - JOUR AU - Cummings, J. AU - Zhong, K. AU - Cordes, D. PY - 2017 DA - 2017// TI - Drug development in Alzheimer’s disease: the role of default mode network assessment in phase II JO - US Neurol VL - 13 UR - https://doi.org/10.17925/USN.2017.13.02.67 DO - 10.17925/USN.2017.13.02.67 ID - Cummings2017 ER - TY - JOUR AU - Schultz, A. P. AU - Chhatwal, J. P. AU - Hedden, T. AU - Mormino, E. C. AU - Hanseeuw, B. J. AU - Sepulcre, J. PY - 2017 DA - 2017// TI - Phases of hyperconnectivity and hypoconnectivity in the default mode and salience networks track with amyloid and tau in clinically normal individuals JO - J Neurosci VL - 37 UR - https://doi.org/10.1523/JNEUROSCI.3263-16.2017 DO - 10.1523/JNEUROSCI.3263-16.2017 ID - Schultz2017 ER - TY - JOUR AU - Sepulcre, J. AU - Sabuncu, M. R. AU - Li, Q. AU - Fakhri, G. AU - Sperling, R. AU - Johnson, K. A. PY - 2017 DA - 2017// TI - Tau and amyloid beta proteins distinctively associate to functional network changes in the aging brain JO - Alzheimers Dement VL - 13 UR - https://doi.org/10.1016/j.jalz.2017.02.011 DO - 10.1016/j.jalz.2017.02.011 ID - Sepulcre2017 ER - TY - JOUR AU - Buckley, R. F. AU - Schultz, A. P. AU - Hedden, T. AU - Papp, K. V. AU - Hanseeuw, B. J. AU - Marshall, G. PY - 2017 DA - 2017// TI - Functional network integrity presages cognitive decline in preclinical Alzheimer disease JO - Neurology. VL - 89 UR - https://doi.org/10.1212/WNL.0000000000004059 DO - 10.1212/WNL.0000000000004059 ID - Buckley2017 ER - TY - JOUR AU - Koch, K. AU - Myers, N. E. AU - Gottler, J. AU - Pasquini, L. AU - Grimmer, T. AU - Forster, S. PY - 2015 DA - 2015// TI - Disrupted intrinsic networks link amyloid-beta pathology and impaired cognition in prodromal Alzheimer’s disease JO - Cereb Cortex VL - 25 UR - https://doi.org/10.1093/cercor/bhu151 DO - 10.1093/cercor/bhu151 ID - Koch2015 ER - TY - JOUR AU - Weiler, M. AU - Campos, B. M. AU - Nogueira, M. H. AU - Pereira Damasceno, B. AU - Cendes, F. AU - Balthazar, M. L. PY - 2014 DA - 2014// TI - Structural connectivity of the default mode network and cognition in Alzheimers disease JO - Psychiatry Res VL - 223 UR - https://doi.org/10.1016/j.pscychresns.2014.04.008 DO - 10.1016/j.pscychresns.2014.04.008 ID - Weiler2014 ER - TY - JOUR AU - Wilson, F. J. AU - Danjou, P. PY - 2015 DA - 2015// TI - Early decision-making in drug development: the potential role of pharmaco-EEG and pharmaco-sleep JO - Neuropsychobiology. VL - 72 UR - https://doi.org/10.1159/000382022 DO - 10.1159/000382022 ID - Wilson2015 ER - TY - JOUR AU - Wilson, F. J. AU - Leiser, S. C. AU - Ivarsson, M. AU - Christensen, S. R. AU - Bastlund, J. F. PY - 2014 DA - 2014// TI - Can pharmaco-electroencephalography help improve survival of central nervous system drugs in early clinical development? JO - Drug Discov Today VL - 19 UR - https://doi.org/10.1016/j.drudis.2013.08.001 DO - 10.1016/j.drudis.2013.08.001 ID - Wilson2014 ER - TY - JOUR AU - Chen, M. K. AU - Mecca, A. P. AU - Naganawa, M. AU - Finnema, S. J. AU - Toyonaga, T. AU - Lin, S. F. PY - 2018 DA - 2018// TI - Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging JO - JAMA Neurol. VL - 75 UR - https://doi.org/10.1001/jamaneurol.2018.1836 DO - 10.1001/jamaneurol.2018.1836 ID - Chen2018 ER - TY - JOUR AU - Liu, E. AU - Schmidt, M. E. AU - Margolin, R. AU - Sperling, R. AU - Koeppe, R. AU - Mason, N. S. PY - 2015 DA - 2015// TI - Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials JO - Neurology. VL - 85 UR - https://doi.org/10.1212/WNL.0000000000001877 DO - 10.1212/WNL.0000000000001877 ID - Liu2015 ER - TY - JOUR AU - Panza, F. AU - Solfrizzi, V. AU - Imbimbo, B. P. AU - Giannini, M. AU - Santamato, A. AU - Seripa, D. PY - 2014 DA - 2014// TI - Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease JO - Expert Rev Neurother VL - 14 UR - https://doi.org/10.1586/14737175.2014.945522 DO - 10.1586/14737175.2014.945522 ID - Panza2014 ER - TY - JOUR AU - Cummings, J. AU - Blennow, K. AU - Johnson, K. AU - Keeley, M. AU - Bateman, R. J. AU - Molinuevo, J. L. PY - 2019 DA - 2019// TI - Anti-tau trials for Alzheimer’s disease: a report from the EU/US/CTAD Task Force JO - J Prev Alzheimers Dis VL - 6 ID - Cummings2019 ER - TY - JOUR AU - Apostolova, L. G. AU - Zarow, C. AU - Biado, K. AU - Hurtz, S. AU - Boccardi, M. AU - Somme, J. PY - 2015 DA - 2015// TI - Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol JO - Alzheimers Dement VL - 11 UR - https://doi.org/10.1016/j.jalz.2015.01.001 DO - 10.1016/j.jalz.2015.01.001 ID - Apostolova2015 ER - TY - JOUR AU - Csernansky, J. G. AU - Hamstra, J. AU - Wang, L. AU - McKeel, D. AU - Price, J. L. AU - Gado, M. PY - 2004 DA - 2004// TI - Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects JO - Alzheimer Dis Assoc Disord VL - 18 ID - Csernansky2004 ER - TY - JOUR AU - Whitwell, J. L. AU - Jack, C. R. AU - Pankratz, V. S. AU - Parisi, J. E. AU - Knopman, D. S. AU - Boeve, B. F. PY - 2008 DA - 2008// TI - Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease JO - Neuroimage. VL - 39 UR - https://doi.org/10.1016/j.neuroimage.2007.10.001 DO - 10.1016/j.neuroimage.2007.10.001 ID - Whitwell2008 ER - TY - JOUR AU - Fox, N. C. AU - Black, R. S. AU - Gilman, S. AU - Rossor, M. N. AU - Griffith, S. G. AU - Jenkins, L. PY - 2005 DA - 2005// TI - Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease JO - Neurology. VL - 64 UR - https://doi.org/10.1212/01.WNL.0000159743.08996.99 DO - 10.1212/01.WNL.0000159743.08996.99 ID - Fox2005 ER - TY - JOUR AU - Novak, G. AU - Fox, N. AU - Clegg, S. AU - Nielsen, C. AU - Einstein, S. AU - Lu, Y. PY - 2015 DA - 2015// TI - Changes in brain volume with bapineuzumab in mild to moderate Alzheimer’s disease JO - J Alzheimers Dis VL - 49 UR - https://doi.org/10.3233/JAD-150448 DO - 10.3233/JAD-150448 ID - Novak2015 ER - TY - JOUR AU - Mattsson, N. AU - Andreasson, U. AU - Zetterberg, H. AU - Blennow, K. PY - 2017 DA - 2017// TI - Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease JO - JAMA Neurol VL - 74 UR - https://doi.org/10.1001/jamaneurol.2016.6117 DO - 10.1001/jamaneurol.2016.6117 ID - Mattsson2017 ER - TY - JOUR AU - Johnson, K. A. AU - Schultz, A. AU - Betensky, R. A. AU - Becker, J. A. AU - Sepulcre, J. AU - Rentz, D. PY - 2016 DA - 2016// TI - Tau positron emission tomographic imaging in aging and early Alzheimer disease JO - Ann Neurol VL - 79 UR - https://doi.org/10.1002/ana.24546 DO - 10.1002/ana.24546 ID - Johnson2016 ER - TY - JOUR AU - Tarawneh, R. AU - Head, D. AU - Allison, S. AU - Buckles, V. AU - Fagan, A. M. AU - Ladenson, J. H. PY - 2015 DA - 2015// TI - Cerebrospinal fluid markers of neurodegeneration and rates of brain atrophy in early Alzheimer disease JO - JAMA Neurol. VL - 72 UR - https://doi.org/10.1001/jamaneurol.2015.0202 DO - 10.1001/jamaneurol.2015.0202 ID - Tarawneh2015 ER - TY - JOUR AU - Henley, D. AU - Raghavan, N. AU - Sperling, R. AU - Aisen, P. AU - Raman, R. AU - Romano, G. PY - 2019 DA - 2019// TI - Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease JO - N Engl J Med VL - 380 UR - https://doi.org/10.1056/NEJMc1813435 DO - 10.1056/NEJMc1813435 ID - Henley2019 ER - TY - JOUR AU - Sperling, R. A. AU - Jack, C. R. AU - Black, S. E. AU - Frosch, M. P. AU - Greenberg, S. M. AU - Hyman, B. T. PY - 2011 DA - 2011// TI - Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup JO - Alzheimers Dement VL - 7 UR - https://doi.org/10.1016/j.jalz.2011.05.2351 DO - 10.1016/j.jalz.2011.05.2351 ID - Sperling2011 ER - TY - JOUR AU - Ketter, N. AU - Brashear, H. R. AU - Bogert, J. AU - Di, J. AU - Miaux, Y. AU - Gass, A. PY - 2017 DA - 2017// TI - Central review of amyloid-related imaging abnormalities in two phase III clinical trials of bapineuzumab in mild-to-moderate Alzheimer’s disease patients JO - J Alzheimers Dis VL - 57 UR - https://doi.org/10.3233/JAD-160216 DO - 10.3233/JAD-160216 ID - Ketter2017 ER - TY - JOUR AU - Ostrowitzki, S. AU - Lasser, R. A. AU - Dorflinger, E. AU - Scheltens, P. AU - Barkhof, F. AU - Nikolcheva, T. PY - 2017 DA - 2017// TI - A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease JO - Alzheimers Res Ther VL - 9 UR - https://doi.org/10.1186/s13195-017-0318-y DO - 10.1186/s13195-017-0318-y ID - Ostrowitzki2017 ER - TY - JOUR AU - Dubois, B. AU - Feldman, H. H. AU - Jacova, C. AU - Cummings, J. L. AU - Dekosky, S. T. AU - Barberger-Gateau, P. PY - 2010 DA - 2010// TI - Revising the definition of Alzheimer’s disease: a new lexicon JO - Lancet Neurol VL - 9 UR - https://doi.org/10.1016/S1474-4422(10)70223-4 DO - 10.1016/S1474-4422(10)70223-4 ID - Dubois2010 ER - TY - JOUR AU - Dubois, B. AU - Feldman, H. H. AU - Jacova, C. AU - Hampel, H. AU - Molinuevo, J. L. AU - Blennow, K. PY - 2014 DA - 2014// TI - Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70090-0 DO - 10.1016/S1474-4422(14)70090-0 ID - Dubois2014 ER - TY - JOUR AU - Herscovici, R. AU - Kutyifa, V. AU - Barsheshet, A. AU - Solomon, S. AU - McNitt, S. AU - Polonsky, B. PY - 2015 DA - 2015// TI - Early intervention and long-term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms JO - Eur J Heart Fail VL - 17 UR - https://doi.org/10.1002/ejhf.281 DO - 10.1002/ejhf.281 ID - Herscovici2015 ER - TY - JOUR AU - Reiman, E. M. AU - Langbaum, J. B. AU - Tariot, P. N. AU - Lopera, F. AU - Bateman, R. J. AU - Morris, J. C. PY - 2016 DA - 2016// TI - CAP--advancing the evaluation of preclinical Alzheimer disease treatments JO - Nat Rev Neurol VL - 12 UR - https://doi.org/10.1038/nrneurol.2015.177 DO - 10.1038/nrneurol.2015.177 ID - Reiman2016 ER - TY - JOUR AU - Sperling, R. A. AU - Jack, C. R. AU - Aisen, P. S. PY - 2011 DA - 2011// TI - Testing the right target and right drug at the right stage JO - Sci Transl Med VL - 3 UR - https://doi.org/10.1126/scitranslmed.3002609 DO - 10.1126/scitranslmed.3002609 ID - Sperling2011 ER - TY - JOUR AU - Sperling, R. AU - Mormino, E. AU - Johnson, K. PY - 2014 DA - 2014// TI - The evolution of preclinical Alzheimer’s disease: implications for prevention trials JO - Neuron. VL - 84 UR - https://doi.org/10.1016/j.neuron.2014.10.038 DO - 10.1016/j.neuron.2014.10.038 ID - Sperling2014 ER - TY - JOUR AU - Cox, C. G. AU - Ryan, B. A. M. AU - Gillen, D. L. AU - Grill, J. D. PY - 2019 DA - 2019// TI - A preliminary study of clinical trial enrollment decisions among people with mild cognitive impairment and their study partners JO - Am J Geriatr Psychiatry VL - 27 UR - https://doi.org/10.1016/j.jagp.2018.10.016 DO - 10.1016/j.jagp.2018.10.016 ID - Cox2019 ER - TY - JOUR AU - Romero, K. AU - Ito, K. AU - Rogers, J. A. AU - Polhamus, D. AU - Qiu, R. AU - Stephenson, D. PY - 2015 DA - 2015// TI - The future is now: model-based clinical trial design for Alzheimer’s disease JO - Clin Pharmacol Ther VL - 97 UR - https://doi.org/10.1002/cpt.16 DO - 10.1002/cpt.16 ID - Romero2015 ER - TY - JOUR AU - Weintraub, S. AU - Carrillo, M. C. AU - Farias, S. T. AU - Goldberg, T. E. AU - Hendrix, J. A. AU - Jaeger, J. PY - 2018 DA - 2018// TI - Measuring cognition and function in the preclinical stage of Alzheimer’s disease JO - Alzheimers Dement (N Y). VL - 4 ID - Weintraub2018 ER - TY - JOUR AU - Langbaum, J. B. AU - Hendrix, S. B. AU - Ayutyanont, N. AU - Chen, K. AU - Fleisher, A. S. AU - Shah, R. C. PY - 2014 DA - 2014// TI - An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer’s disease JO - Alzheimers Dement VL - 10 UR - https://doi.org/10.1016/j.jalz.2014.02.002 DO - 10.1016/j.jalz.2014.02.002 ID - Langbaum2014 ER - TY - JOUR AU - Morris, J. C. PY - 1993 DA - 1993// TI - The Clinical Dementia Rating (CDR): current version and scoring rules JO - Neurology. VL - 43 UR - https://doi.org/10.1212/WNL.43.11.2412-a DO - 10.1212/WNL.43.11.2412-a ID - Morris1993 ER - TY - JOUR AU - Rosen, W. G. AU - Mohs, R. C. AU - Davis, K. L. PY - 1984 DA - 1984// TI - A new rating scale for Alzheimer’s disease JO - Am J Psychiatry VL - 141 UR - https://doi.org/10.1176/ajp.141.11.1356 DO - 10.1176/ajp.141.11.1356 ID - Rosen1984 ER - TY - JOUR AU - Harrison, J. AU - Minassian, S. L. AU - Jenkins, L. AU - Black, R. S. AU - Koller, M. AU - Grundman, M. PY - 2007 DA - 2007// TI - A neuropsychological test battery for use in Alzheimer disease clinical trials JO - Arch Neurol VL - 64 UR - https://doi.org/10.1001/archneur.64.9.1323 DO - 10.1001/archneur.64.9.1323 ID - Harrison2007 ER - TY - JOUR AU - Wang, J. AU - Logovinsky, V. AU - Hendrix, S. B. AU - Stanworth, S. H. AU - Perdomo, C. AU - Xu, L. PY - 2016 DA - 2016// TI - ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials JO - J Neurol Neurosurg Psychiatry VL - 87 UR - https://doi.org/10.1136/jnnp-2015-312383 DO - 10.1136/jnnp-2015-312383 ID - Wang2016 ER - TY - JOUR AU - Schmitt, F. A. AU - Ashford, W. AU - Ernesto, C. AU - Saxton, J. AU - Schneider, L. S. AU - Clark, C. M. PY - 1997 DA - 1997// TI - The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The 6 Study JO - Alzheimer Dis Assoc Disord VL - 11 UR - https://doi.org/10.1097/00002093-199700112-00008 DO - 10.1097/00002093-199700112-00008 ID - Schmitt1997 ER - TY - JOUR AU - Galasko, D. AU - Bennett, D. AU - Sano, M. AU - Ernesto, C. AU - Thomas, R. AU - Grundman, M. PY - 1997 DA - 1997// TI - An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study JO - Alzheimer Dis Assoc Disord VL - 11 UR - https://doi.org/10.1097/00002093-199700112-00005 DO - 10.1097/00002093-199700112-00005 ID - Galasko1997 ER - TY - JOUR AU - Jutten, R. J. AU - Peeters, C. F. W. AU - Leijdesdorff, S. M. J. AU - Visser, P. J. AU - Maier, A. B. AU - Terwee, C. B. PY - 2017 DA - 2017// TI - Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire JO - Alzheimers Dement (Amst) VL - 8 ID - Jutten2017 ER - TY - JOUR AU - Sikkes, S. A. AU - Pijnenburg, Y. A. AU - Knol, D. L. AU - Klerk, E. S. AU - Scheltens, P. AU - Uitdehaag, B. M. PY - 2013 DA - 2013// TI - Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire JO - J Geriatr Psychiatry Neurol VL - 26 UR - https://doi.org/10.1177/0891988713509139 DO - 10.1177/0891988713509139 ID - Sikkes2013 ER - TY - JOUR AU - Vellas, B. AU - Carrillo, M. C. AU - Sampaio, C. AU - Brashear, H. R. AU - Siemers, E. AU - Hampel, H. PY - 2013 DA - 2013// TI - Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force JO - Alzheimers Dement VL - 9 UR - https://doi.org/10.1016/j.jalz.2013.03.007 DO - 10.1016/j.jalz.2013.03.007 ID - Vellas2013 ER - TY - JOUR AU - Das, S. AU - Lo, A. W. PY - 2017 DA - 2017// TI - Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program JO - Contemp Clin Trials VL - 62 UR - https://doi.org/10.1016/j.cct.2017.09.002 DO - 10.1016/j.cct.2017.09.002 ID - Das2017 ER - TY - JOUR AU - Finger, E. C. AU - Berry, S. AU - Cummings, J. AU - Coleman, K. AU - Hsiung, R. AU - Feldman, H. H. PY - 2018 DA - 2018// TI - Adaptive cross-over designs for assessment of symptomatic treatments targeting behavior in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY) JO - Alzheimers Res Ther VL - 10 UR - https://doi.org/10.1186/s13195-018-0427-2 DO - 10.1186/s13195-018-0427-2 ID - Finger2018 ER - TY - JOUR AU - Ritchie, C. W. AU - Molinuevo, J. L. AU - Truyen, L. AU - Satlin, A. AU - Geyten, S. AU - Lovestone, S. PY - 2016 DA - 2016// TI - Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project JO - Lancet Psychiatry VL - 3 UR - https://doi.org/10.1016/S2215-0366(15)00454-X DO - 10.1016/S2215-0366(15)00454-X ID - Ritchie2016 ER - TY - JOUR AU - Bateman, R. J. AU - Benzinger, T. L. AU - Berry, S. AU - Clifford, D. B. AU - Duggan, C. AU - Fagan, A. M. PY - 2017 DA - 2017// TI - The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model JO - Alzheimers Dement VL - 13 UR - https://doi.org/10.1016/j.jalz.2016.07.005 DO - 10.1016/j.jalz.2016.07.005 ID - Bateman2017 ER - TY - JOUR AU - Grill, J. D. AU - Raman, R. AU - Ernstrom, K. AU - Aisen, P. AU - Dowsett, S. A. AU - Chen, Y. F. PY - 2015 DA - 2015// TI - Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials JO - Alzheimers Res Ther VL - 7 UR - https://doi.org/10.1186/s13195-015-0122-5 DO - 10.1186/s13195-015-0122-5 ID - Grill2015 ER - TY - JOUR AU - Henley, D. B. AU - Dowsett, S. A. AU - Chen, Y. F. AU - Liu-Seifert, H. AU - Grill, J. D. AU - Doody, R. S. PY - 2015 DA - 2015// TI - Alzheimer’s disease progression by geographical region in a clinical trial setting JO - Alzheimers Res Ther VL - 7 UR - https://doi.org/10.1186/s13195-015-0127-0 DO - 10.1186/s13195-015-0127-0 ID - Henley2015 ER - TY - JOUR AU - Cummings, J. L. AU - Atri, A. AU - Ballard, C. AU - Boneva, N. AU - Frolich, L. AU - Molinuevo, J. L. PY - 2018 DA - 2018// TI - Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program JO - Alzheimer Res Ther VL - 10 UR - https://doi.org/10.1186/s13195-018-0443-2 DO - 10.1186/s13195-018-0443-2 ID - Cummings2018 ER - TY - JOUR AU - Kennedy, R. E. AU - Cutter, G. R. AU - Wang, G. AU - Schneider, L. S. PY - 2017 DA - 2017// TI - Challenging assumptions about African American participation in Alzheimer disease trials JO - Am J Geriatr Psychiatry VL - 25 UR - https://doi.org/10.1016/j.jagp.2017.04.013 DO - 10.1016/j.jagp.2017.04.013 ID - Kennedy2017 ER - TY - JOUR AU - Cummings, J. L. AU - Aisen, P. AU - Barton, R. AU - Bork, J. AU - Doody, R. AU - Dwyer, J. PY - 2016 DA - 2016// TI - Re-engineering Alzheimer clinical trials: Global Alzheimer Platform Network JO - J Prevent Alz Dis VL - 3 ID - Cummings2016 ER - TY - JOUR AU - Mackin, R. S. AU - Insel, P. S. AU - Truran, D. AU - Finley, S. AU - Flenniken, D. AU - Nosheny, R. PY - 2018 DA - 2018// TI - Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: results from the Brain Health Registry JO - Alzheimers Dement (Amst) VL - 10 ID - Mackin2018 ER - TY - JOUR AU - Nosheny, R. L. AU - Camacho, M. R. AU - Insel, P. S. AU - Flenniken, D. AU - Fockler, J. AU - Truran, D. PY - 2018 DA - 2018// TI - Online study partner-reported cognitive decline in the Brain Health Registry JO - Alzheimers Dement (N Y) VL - 4 ID - Nosheny2018 ER - TY - JOUR AU - Zhong, K. AU - Cummings, J. PY - 2016 DA - 2016// TI - Healthybrains.org: from registry to randomization JO - J Prev Alz Dis. VL - 3 ID - Zhong2016 ER - TY - JOUR AU - Tan, M. H. AU - Thomas, M. AU - MacEachern, M. P. PY - 2015 DA - 2015// TI - Using registries to recruit subjects for clinical trials JO - Contemp Clin Trials. VL - 41 UR - https://doi.org/10.1016/j.cct.2014.12.012 DO - 10.1016/j.cct.2014.12.012 ID - Tan2015 ER - TY - JOUR AU - Paul, S. M. AU - Mytelka, D. S. AU - Dunwiddie, C. T. AU - Persinger, C. C. AU - Munos, B. H. AU - Lindborg, S. R. PY - 2010 DA - 2010// TI - How to improve R&D productivity: the pharmaceutical industry’s grand challenge JO - Nat Rev Drug Discov VL - 9 UR - https://doi.org/10.1038/nrd3078 DO - 10.1038/nrd3078 ID - Paul2010 ER -